2,3-dihydroxypropyl dihydrogen phosphate, disodium salt
分子式
C3H9Na2O6P
分子量
218.05
精确分子量
217.99
SMILES
O=P(O)(O)OCC(O)CO.[Na].[Na]
标准SMILES
[Na].[Na].OCC(O)COP(O)(O)=O
用途
Alirocumab is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor monoclonal antibody indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol (LDL-C). By inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR), alirocumab increases the number of LDLRs available to clear LDL from the circulation, thereby reducing LDL-C levels.